JLABS and MilliporeSigma Discussion Panel Event – Navigating technical and regulatory challenges with confidence

South San Francisco


3:00pm - 6:00pm

It is critical to anticipate and overcome challenges rapidly when transitioning from pre-clinical POC studies into clinical studies in drug development. The earlier you consider the risks and long-term effects of raw materials, technologies and process performance, the higher your chances of succeeding in development.

Key considerations regarding raw materials, supply chain robustness, technology scalability and validation requirements are often underestimated. However, if one of these areas is not properly managed, it could lead to serious project delays and can potentially compromise the development and commercialization of pioneering drug therapies.

This presentation and subsequent panel discussion will:

Bring to light the challenges encountered when going from animal testing to first-in-human studies
Consider factors which can mitigate potential pitfalls
Share ideas how to facilitate a seamless transition

Tom Beil | Vice President of Quality Assurance, MilliporeSigma read bio»
Elizabeth Goodrich | Director of Bioprocess Applications Engineering, MilliporeSigma read bio»
Vince Mecozzi | Scientist for Downstream Purification , Audentes Therapeutics read bio»
Jim Neville | Director of Technology Management - Americas, MilliporeSigma read bio»
Kathy Martin Remington | Principal Scientist, BioReliance read bio»

3:00pm | Registration and Networking
3:30pm | Welcome and Introductions
3:45pm | Presentations: Start with the End in Mind
4:30pm | Panel Discussion
5:30pm | Networking reception
6:30pm | Program Close

Free | General Public

Click Here for More Information

Contact: Nikki Sarantinos
Contact Email:

Event Address:

329 Oyster Point Blvd.
Floor 3
South San Francisco, CA